Genetic LifeSpan launch MyHeartCode, betting that epigenetic data can tell people more about their heart than cholesterol ever did.
There’s a particular kind of dread that comes with a family history of heart disease: you know the risk is there, but a single cholesterol number never quite explains it.
Genetic LifeSpan is betting that a deeper look at your biology can do better, and the company introduced that bet to more than 100 physicians, scientists and longevity insiders at a grand premiere in Beverly Hills last month.
The product is called MyHeartCode, an at-home cardiovascular assessment built with cardiologist Dr Ernst von Schwarz [1]. Rather than a single blood draw and a single number, it’s pitched as a running picture of how your cardiovascular system is aging – built, aging and metabolic function included, to help people have sharper conversations with their doctors before a crisis forces the issue.
Instead of measuring what’s floating in your blood right now, MyHeartCode looks at your DNA methylation, chemical tags on your genes that shift depending on how your body has been functioning lately. The test examines up to 3 million of these sites, known as CpG sites, and uses them to build a picture of biological patterns over roughly the previous three to four months.
That’s the practical difference from a standard cardiovascular panel. A cholesterol test is a photograph of a single moment. Methylation data, according to Genetic LifeSpan, works more like a few months of security footage. It’s less about what’s happening today and more about the pattern building underneath.
The report itself covers more than ten areas: cardiovascular age and how fast it’s aging, metabolic and inflammatory health, immune function, stress biomarkers, nutrient deficiencies, toxin exposure and mitochondrial health, all delivered as a personalized digital report meant to be reviewed with a doctor, not read in isolation.
The case for looking earlier
Von Schwarz, an internationally recognized cardiologist, framed the product around a specific kind of person: someone who’s already had a heart scare, been told they’re at risk, or watched cardiovascular disease move through their family.
“For someone who has already experienced a heart problem, has been told they are at risk, or has watched cardiovascular disease affect their family, the question is not whether heart health matters – it is whether they have enough information to make better decisions,” von Schwarz said. “Cardiovascular health is about far more than a single number or a snapshot in time. MyHeartCode was designed to provide a more comprehensive understanding of cardiovascular aging and the biological factors that may be influencing health over time.”
Genetic LifeSpan’s founder and CEO, Adam Vincent Gilmer, made a similar point in blunter terms.
“Heart disease touches almost every family, and too often people begin paying attention only after something happens,” Gilmer said. “MyHeartCode is about giving people a deeper look at their cardiovascular biology so they can ask better questions, have better conversations with their doctors and become more proactive about their health. If you have heart problems, a family history or simply want to understand how your heart may be aging, better information matters. We don’t want people guessing about their health. We want them testing, understanding and taking informed action with their healthcare team.”
A premiere, not just a press release
The launch itself was staged more like a product unveiling than a typical biotech announcement – guests, a red carpet, remarks from von Schwarz and a room full of the company’s Scientific Advisory Board. It’s a format that’s becoming familiar in the longevity testing world, where the product is as much a lifestyle signal as a diagnostic tool, and the event is part of selling that image.
MyHeartCode is available now in the United States, joining Genetic LifeSpan’s existing lineup that includes its AgeCode biological age report.
Cardiovascular disease is still the single biggest thing standing between people and a long healthspan. It doesn’t matter how well your cellular biology is holding up if your heart gives out first. What makes MyHeartCode notable isn’t the novelty of epigenetic testing itself, which has been creeping into consumer health for a few years now. It’s the attempt to fold heart health specifically into that same personalized, longitudinal framework that biological-age testing has popularized elsewhere in the body.
Whether a methylation-based read on cardiovascular aging actually changes outcomes, rather than just changing how detailed the bad news feels, is the harder question and one that will take longer than a product launch to answer.
